Keyphrases
Secondary Prevention
100%
Randomized Controlled Trial
100%
Meta-analysis
100%
Atherosclerotic Disease
100%
Vorapaxar
100%
Placebo
57%
Ischemic Stroke
42%
Myocardial Infarction
42%
Intracranial Hemorrhage
42%
All-cause Mortality
28%
Repeat Revascularization
28%
Increasing Risk
14%
Atherosclerotic Cardiovascular Disease (ASCVD)
14%
High Risk
14%
Myocardial Ischemia
14%
Cardiovascular Mortality
14%
Bleeding
14%
Efficacy Endpoint
14%
Risk Ratio
14%
Major Bleeding
14%
MEDLINE
14%
Random Effects Model
14%
CINAHL
14%
Embase
14%
Cochrane Database
14%
Safety Endpoints
14%
Web of Science Database
14%
Minor Bleeding
14%
Standard Medical Therapy
14%
EBSCO
14%
CV Death
14%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Vorapaxar
100%
Diseases
100%
Placebo
57%
Heart Infarction
42%
Brain Hemorrhage
42%
Brain Ischemia
42%
All Cause Mortality
28%
Coronary Artery Atherosclerosis
14%
Combination Therapy
14%
Bleeding
14%
Random Effects Model
14%
Cardiovascular Mortality
14%